Rigel Pharmaceuticals, Inc.
TGF- inhibitors

Last updated:

Abstract:

Disclosed are aryl pyrimidine compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, R and R' are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-.beta. superfamily, and can be used to treat disease by blocking such activity. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

29 Mar 2016

Issue date:

1 Jun 2021